Literature DB >> 27854161

Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells.

Jie Gao1,2, Wei Li3, Yajun Guo3, Si-Shen Feng3,4,5.   

Abstract

Cancer stem cells (CSCs) are original cancer cells that are of characteristics associated with normal stem cells. CSCs are toughest against various treatments and thus responsible for cancer metastasis and recurrence. Therefore, development of specific and effective treatment of CSCs plays a key role in improving survival and life quality of cancer patients, especially those in the metastatic stage. Nanomedicine strategies, which include prodrugs, micelles, liposomes and nanoparticles of biodegradable polymers, could substantially improve the therapeutic index of conventional therapeutics due to its manner of sustained, controlled and targeted delivery of high transportation efficiency across the cell membrane and low elimination by intracellular autophagy, and thus provide a practical solution to solve the problem encountered in CSCs treatment. This review gives briefly the latest information to summarize the concept, strategies, mechanisms and current status as well as future promises of nanomedicine strategies for treatment of CSCs.

Entities:  

Keywords:  biodegradable polymers; cancer nanotechnology; drug targeting; molecular biomaterials; multidrug resistance; multimodality treatment; pharmaceutical nanotechnology

Mesh:

Substances:

Year:  2016        PMID: 27854161     DOI: 10.2217/nnm-2016-0261

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  15 in total

1.  [Targeted killing of CD133+ lung cancer stem cells using paclitaxel-loaded PLGA-PEG nanoparticles with CD133 aptamers].

Authors:  L Pang; X Huang; L Zhu; H Xiao; M Li; H Guan; J Gao; H Jin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

2.  The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles.

Authors:  Yi Mi; Yuqin Huang; Jie Deng
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

3.  Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.

Authors:  Yi-Bin Zeng; Zuo-Chong Yu; Yan-Ni He; Tong Zhang; Ling-Bo Du; Yin-Mei Dong; Huai-Wen Chen; Ying-Ying Zhang; Wu-Qing Wang
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

4.  Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles.

Authors:  Yinan Zhong; Fenghua Meng; Chao Deng; Xinliang Mao; Zhiyuan Zhong
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  The combination therapy of salinomycin and gefitinib using poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles for targeting both lung cancer stem cells and cancer cells.

Authors:  Yu Zhang; Qi Zhang; Jing Sun; Huijie Liu; Qingfeng Li
Journal:  Onco Targets Ther       Date:  2017-11-27       Impact factor: 4.147

6.  Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.

Authors:  Dazhong Chen; Xiaoli Pan; Fangyuan Xie; Ying Lu; Hao Zou; Chuan Yin; Yu Zhang; Jie Gao
Journal:  Int J Nanomedicine       Date:  2018-10-25

7.  Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells.

Authors:  Zuochong Yu; Fangyi Chen; Xiaoxia Qi; Yinmei Dong; Yingying Zhang; Zhe Ge; Guoping Cai; Xinchao Zhang
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

8.  Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.

Authors:  Jun Li; Wenqing Xu; Xiaoli Yuan; Huaiwen Chen; Hao Song; Bingquan Wang; Jun Han
Journal:  Int J Nanomedicine       Date:  2017-09-18

9.  Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.

Authors:  Xiaolong Huang; Jingsong Huang; Dewen Leng; Shuo Yang; Qi Yao; Jin Sun; Jun Hu
Journal:  World J Surg Oncol       Date:  2017-08-30       Impact factor: 2.754

10.  All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitro.

Authors:  Xingyu Chen; Zhiyuan Zhang; Shengfeng Yang; Hairong Chen; Dan Wang; Jun Li
Journal:  Onco Targets Ther       Date:  2018-09-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.